Literature DB >> 17088338

Pyridoxine-dependent seizures in Dutch patients: diagnosis by elevated urinary alpha-aminoadipic semialdehyde levels.

Levinus A Bok1, Eduard Struys, Michel A A P Willemsen, Jasper V Been, Cornelis Jakobs.   

Abstract

BACKGROUND: Pyridoxine-dependent seizures (PDS) is a rare, autosomal recessively inherited disorder. Recently alpha-aminoadipic semialdehyde (alpha-AASA) dehydrogenase deficiency was identified as a major cause of PDS, which causes accumulation of both alpha-AASA and pipecolic acid (PA) in body fluids.
METHODS: We studied urinary and plasma alpha-AASA and PA levels in 12 Dutch clinically diagnosed patients with PDS.
RESULTS: Alpha-AASA was elevated in both urine and plasma in 10 patients. In these patients plasma PA levels were also elevated but urinary PA levels were normal. DISCUSSION: In all patients with clinically definite PDS, and in most patients with probable or possible PDS, the clinical diagnosis of PDS could be confirmed at the metabolite level. Non-invasive urinary screening for alpha-AASA accumulation provides a reliable tool to diagnose PDS and can save these patients from the classical and potentially dangerous pyridoxine withdrawal test to prove PDS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17088338      PMCID: PMC2083882          DOI: 10.1136/adc.2006.103192

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  8 in total

1.  Epidemiology of pyridoxine dependent seizures in the Netherlands.

Authors:  J V Been; L A Bok; P Andriessen; W O Renier
Journal:  Arch Dis Child       Date:  2005-09-13       Impact factor: 3.791

2.  Pipecolic acid: a diagnostic marker in pyridoxine-dependent epilepsy.

Authors:  Michèl A A P Willemsen; Annelies M C Mavinkurve-Groothuis; Ron A Wevers; Jan J Rotteveel; Cornelis Jakobs
Journal:  Ann Neurol       Date:  2005-10       Impact factor: 10.422

3.  Mutations in antiquitin in individuals with pyridoxine-dependent seizures.

Authors:  Philippa B Mills; Eduard Struys; Cornelis Jakobs; Barbara Plecko; Peter Baxter; Matthias Baumgartner; Michèl A A P Willemsen; Heymut Omran; Uta Tacke; Birgit Uhlenberg; Bernhard Weschke; Peter T Clayton
Journal:  Nat Med       Date:  2006-02-19       Impact factor: 53.440

Review 4.  Pyridoxine-dependent seizures: a clinical and biochemical conundrum.

Authors:  Peter Baxter
Journal:  Biochim Biophys Acta       Date:  2003-04-11

5.  Stable isotope dilution analysis of pipecolic acid in cerebrospinal fluid, plasma, urine and amniotic fluid using electron capture negative ion mass fragmentography.

Authors:  R M Kok; L Kaster; A P de Jong; B Poll-Thé; J M Saudubray; C Jakobs
Journal:  Clin Chim Acta       Date:  1987-09-30       Impact factor: 3.786

6.  Pipecolic acid elevation in plasma and cerebrospinal fluid of two patients with pyridoxine-dependent epilepsy.

Authors:  B Plecko; S Stöckler-Ipsiroglu; E Paschke; W Erwa; E A Struys; C Jakobs
Journal:  Ann Neurol       Date:  2000-07       Impact factor: 10.422

7.  Pipecolic acid as a diagnostic marker of pyridoxine-dependent epilepsy.

Authors:  B Plecko; C Hikel; G-C Korenke; B Schmitt; M Baumgartner; F Baumeister; C Jakobs; E Struys; W Erwa; S Stöckler-Ipsiroglu
Journal:  Neuropediatrics       Date:  2005-06       Impact factor: 1.947

8.  Epidemiology of pyridoxine dependent and pyridoxine responsive seizures in the UK.

Authors:  P Baxter
Journal:  Arch Dis Child       Date:  1999-11       Impact factor: 3.791

  8 in total
  13 in total

1.  Long-Term Follow-up of a Successfully Treated Case of Congenital Pyridoxine-Dependent Epilepsy.

Authors:  Malcolm Proudfoot; Philip Jardine; Agne Straukiene; Rupert Noad; Andrew Parrish; Sian Ellard; Stuart Weatherby
Journal:  JIMD Rep       Date:  2013-02-12

2.  Roth spots in pyridoxine dependent epilepsy.

Authors:  Levinus A Bok; Feico Halbertsma; Frank Kerkhoff; Cornelis Jakobs; Carola Duijsters; Michèl Willemsen
Journal:  BMJ Case Rep       Date:  2011-08-17

Review 3.  New treatment paradigms in neonatal metabolic epilepsies.

Authors:  P L Pearl
Journal:  J Inherit Metab Dis       Date:  2009-02-24       Impact factor: 4.982

4.  Pyridoxine responsiveness in novel mutations of the PNPO gene.

Authors:  Barbara Plecko; Karl Paul; Philippa Mills; Peter Clayton; Eduard Paschke; Oliver Maier; Oswald Hasselmann; Gudrun Schmiedel; Simone Kanz; Mary Connolly; Nicole Wolf; Eduard Struys; Sylvia Stockler; Lucia Abela; Doris Hofer
Journal:  Neurology       Date:  2014-03-21       Impact factor: 9.910

5.  Clinical features and the management of pyridoxine-dependent and pyridoxine-responsive seizures: review of 63 North American cases submitted to a patient registry.

Authors:  Gregory J Basura; Shawn P Hagland; Anna M Wiltse; Sidney M Gospe
Journal:  Eur J Pediatr       Date:  2008-09-02       Impact factor: 3.183

6.  Antenatal treatment in two Dutch families with pyridoxine-dependent seizures.

Authors:  Levinus A Bok; Jasper V Been; Eduard A Struys; Cornelis Jakobs; Elisabeth A M Rijper; Michèl A Willemsen
Journal:  Eur J Pediatr       Date:  2009-07-09       Impact factor: 3.183

Review 7.  The molecular biology of genetic-based epilepsies.

Authors:  Hao Deng; Xiaofei Xiu; Zhi Song
Journal:  Mol Neurobiol       Date:  2013-08-10       Impact factor: 5.590

8.  The measurement of urinary Δ¹-piperideine-6-carboxylate, the alter ego of α-aminoadipic semialdehyde, in Antiquitin deficiency.

Authors:  Eduard A Struys; Levinus A Bok; Dina Emal; Saskia Houterman; Michel A Willemsen; Cornelis Jakobs
Journal:  J Inherit Metab Dis       Date:  2012-01-17       Impact factor: 4.982

Review 9.  Recent advances in amino acid and organic acid metabolism.

Authors:  J V Leonard
Journal:  J Inherit Metab Dis       Date:  2007-01-19       Impact factor: 4.750

10.  Comprehensive Analysis of Aldehyde Dehydrogenases (ALDHs) and Its Significant Role in Hepatocellular Carcinoma.

Authors:  Senbang Yao; Wenjun Chen; He Zuo; Ziran Bi; Xiuqing Zhang; Lulian Pang; Yanyan Jing; Xiangxiang Yin; Huaidong Cheng
Journal:  Biochem Genet       Date:  2021-12-20       Impact factor: 2.220

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.